Skip to content
Buy This GLP
← Research
Evidence

What Are the Side Effects of a GLP-1? What Is Measured, by How Much

Studies measure common digestive symptoms and rarer complications in different ways. See what the available comparisons can tell you about each.

Editorial profile: Neil SandersBuy This GLP Editorial Team9 min read
Severe gastrointestinal events, head to head1.0sema vs dulatirz vs dulatirz vs sema132,751 matched pairs. Every interval crosses the line.

In 55 placebo-controlled trials covering 106,395 people, the risk ratio was 1.46 for gallstones and 2.19 for reflux [2]. That is about two extra gallstone cases and four extra reflux cases per thousand. The authors found less evidence of a change in other gastrointestinal or biliary risks. The separate review of cough during GLP-1 treatment covers a symptom outside that analysis. Reflux and cough can have other causes.

In a phase 2b trial in China, gastrointestinal events occurred in 51.9% of participants on weekly semaglutide 1 mg and 81.8% to 87.3% of participants across the bofanglutide groups. Most were grade 1 or 2[3]. These rates describe the drugs and regimens tested in adults with type 2 diabetes.

A separate records study of tirzepatide users with obesity and heart failure with preserved ejection fraction found a lower hazard of recorded nausea and vomiting in men than women (hazard ratio 0.50, 95% CI 0.37 to 0.67)[4]. The review of side-effect differences by sex discusses the limits of diagnosis codes. The estimate applies to this matched cohort.

The matched study compared a composite of severe events. The analysis of tirzepatide’s costs and outcomes covers a separate question about value. The severe-event comparison cannot tell you how likely you are to experience everyday nausea on either drug.

What was compared

A new-user, active-comparator cohort study identified adults with type 2 diabetes starting dulaglutide, semaglutide or tirzepatide. The window ran from January 2019 to August 2024. It built three pairwise comparisons, propensity-matched 1:1 within each [1].

That produced 65,238 matched pairs for semaglutide against dulaglutide, 20,893 for tirzepatide against dulaglutide, and 46,620 for tirzepatide against semaglutide. The primary outcome was a composite of acute pancreatitis, biliary disease, bowel obstruction, gastroparesis and severe constipation.

How the severe-event estimates compared

Semaglutide against dulaglutide gave 0.96 (95% CI 0.87 to 1.06). Tirzepatide against dulaglutide gave 0.96 (95% CI 0.77 to 1.20). Tirzepatide against semaglutide gave 1.07 (95% CI 0.90 to 1.26).

All three confidence intervals include 1.0. For tirzepatide versus semaglutide, the interval also includes estimates consistent with lower or higher risk. The study leaves uncertainty about the size and direction of any difference.

Our guide to rash during GLP-1 treatment examines the evidence for skin reactions. The analysis of semaglutide trial discontinuation instead examines stopping because of adverse events. The studies report different outcomes, so check what each counted.

Set against what the two cost

Across the 158 injected semaglutide figures and 159 injected tirzepatide figures recorded here, the median billed rates are $186 and $269. That is a difference of $83, or $996 over a year. Roster read November 2026.

These are prices for published offers. They do not tell you which drug you will tolerate better. Discuss individual risks with your prescriber.

The comparison a buyer can actually make

The monthly price guide explains which charges go into the estimate. If your dose changes, the guide to pricing at higher doses explains why a starting quote can understate later costs. Ask the provider for the refill price at the dose on your prescription.

Frequently asked

Is tirzepatide harder on the stomach than semaglutide?
In 46,620 matched pairs, the estimated hazard ratio for severe events was 1.07, with a 95% confidence interval of 0.90 to 1.26. The study did not assess everyday nausea.
What counted as a gastrointestinal event?
A composite of acute pancreatitis, biliary disease, bowel obstruction, gastroparesis and severe constipation. Everyday nausea was not part of it.
Does this apply to weight-management use?
The study was in adults with type 2 diabetes, where dosing does not always match weight practice, and the authors name residual confounding by glycemic control and BMI as a limitation.
So what should the price difference buy?
Compare the medication, services and refill terms included in each quote. The study did not measure how often either drug caused everyday symptoms.

Sources

  1. [1] Crisafulli S, et al. (2026). Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes Annals of Internal Medicine. PMID 41183330
  2. [2] Chiang CH, et al. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis Gastroenterology. PMID 40499738
  3. [3] Liu M, Cheng Z, Lu L, Cai H, et al. (2026). Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes: A Phase 2b Randomized Clinical Trial Annals of Internal Medicine. PMID 42372276
  4. [4] Mortada I, et al. (2026). Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide Therapeutic Advances in Cardiovascular Disease. PMID 42605954

More in Evidence